Medicor Cancer Centres / Sano Via Wellness
4576 Yonge St
Toronto, Ontario M2N6N4
World Orgnization of Natural Medicines, Board of Integrative Medicine, Fellow of American Academy of Ozone Therapy
Dr. Khan is a graduate of the University of Toronto, Faculty of Medicine (1992). He completed his certification in Family Medicine in 1994. Dr. Khan began working with end stage cancer patients from the beginning of his career by providing home-based pain and symptom management and 24/7 on-call. He co-founded a charitable corporation (Palliative Interdisciplinary Network) to help support his efforts.
Through his work with cancer patients, he learned that many patients who had failed all standard therapies were looking for new options outside of what was available under the Canadian health system. Due to such patient demand, he co-founded Medicor Cancer Centres, an integrative private cancer clinic, with his wife in 2006. The goal of this clinic was to provide better therapies for cancer patients, without the limitations of the public system.
Since 2007, Dr. Khan gained international recognition and has been treating patients from all over the world due to his unique non-toxic approaches to cancer treatment. He is privileged to be the first doctor in the world to prescribe off-label sodium dichloroacetate (DCA) to treat cancer with positive results. As a result, he now has the most DCA experience of any physician in the world with over 2000 cancer patients treated. He also has taken the refreshing approach of openly sharing the results of his treatments with the not just the medical community, but with the public through this website in the form of observational data and case reports. This allows patients and physicians everywhere to benefit from his knowledge, and learn to use DCA safely and effectively.
In 2013, Dr . Khan was honoured to be contacted by Dr. Ken Matsumura of Berkeley California, with the news that Medicor was selected to be the first Canadian clinic to offer S.E.F. Chemotherapy, a unique and powerful chemo-immunotherapy. Although Dr. Khan first discovered Dr. Matsumura’s amazing research in 2006, S.E.F. Chemo was still being evaluated and data was being collected, so the therapy could not be given in Canada. Finally in 2013, Dr. Matsumura began preparation to open a new satellite clinic. Medicor was selected to administer this amazing therapy. Over 4 years, Medicor patients benefited greatly. With low side effects and strong responses seen in nearly 90% of stage 4 cancers, this therapy generated a great deal of excitement as word spread throughout the community. Paradoxically, oncologists vigorously opposed the therapy despite clear data of its safety and success. As a result, Dr. Khan lost the ability to administer S.E.F. chemo in 2017.
Through ongoing advancement, Dr. Khan has created a cancer clinic which allows patients to receive optimized care by integrating conventional, naturopathic and off-label therapies. He is constantly exploring unique and cutting edge solutions to the varied problems that cancer patients and their families face on a day-to-day basis.
Contributions to Orthomolecular Medicine
Speaker, 50th Annual International Orthomolecular Medicine Today Conference
Khan A, Andrews D, Shainhouse J, Blackburn AC (2017) Long-term stabilization of metastatic melanoma with sodium dichloroacetate. World J Clin Oncol. 8(4):371-377
Khan A, Andrews D, Blackburn AC (2016) Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy. World J Clin Cases. 4(10):336-343
Khan A, Marier D, Marsden E, Andrews D, Eliaz I (2014) A Novel Form of Dichloroacetate Therapy for Patients With Advanced Cancer: A Report of 3 Cases. Altern Ther Health Med. 20(S2):21-28.
Kahn A (2014) “Long-term remission of adenoid cystic tongue carcinoma with low dose naltrexone and vitamin D3 – a case report”. Oral Health Dent Manag. 13(3):721-4.
Corradetti R, Khan, A (2014) “Chemotherapy-Induced Peripheral Neuropathy”. Journal of Integrated Healthcare Practitioners
Khan A, Stavros E, Kroeker A (2013) “Vitamin E: Obstacles and Opportunities in Cancer Prevention and Treatment”. Journal of Integrated Healthcare Practitioners
Bradford, S, Khan A (2013) “Individualizing Chemotherapy using the Anti-Diabetic Drug, Metformin, an Adjuvant: An Exploratory Study”. J Cancer Sci Ther. 5.3
Kahn A (2012) “Case Report of Long Term Complete Remission of Metastatic Renal Squamous Cell Carcinoma After Palliative Radiotherapy and Adjuvant Dichloroacetate”. Advances in Cancer Research and Treatment. [Epub]
Kahn A (2011) “Use of Oral Dichloroacetate for Palliation of Leg Pain Arising from Metastatic Poorly Differentiated Carcinoma: A Case Report.” J Palliat Med. [Epub ahead of print]